Novartis Q2 Preview: All Eyes On New Launches
The Basel-headquartered company has launched three high-profile drugs in the past couple of months. Analysts are waiting to see what initial impact these potential future growth drivers are having.
You may also be interested in...
All change at the top for Sanofi which has poached Novartis pharma chief Paul Hudson to succeed Olivier Brandicourt as CEO.
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.